pre-IPO PHARMA

COMPANY OVERVIEW

OMEICOS Therapeutics’ is focused on developing therapeutics that can be broadly deployed in inflammatory, cardiovascular, ophthalmology and other disease indications using its proprietary technology and extensive knowledge of omega-3 fatty acid metabolism and biology.


LOCATION


THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Inflammatory Disease
  • Ophthalmology

  • WEBSITE

    https://www.omeicos.com/investors.html


    CAREER WEBSITE

    https://omeicos.com/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Sep 3, 2019

    OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer


    Apr 29, 2019

    OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation


    Feb 11, 2019

    OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter


    Nov 2, 2018

    OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation


    Nov 2, 2018

    Forbion Leads €17M Series C Financing of Omeicos Therapeutics


    For More Press Releases


    Google Analytics Alternative